机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[2]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, & Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China四川大学华西医院[3]Laboratory of Human Diseases & Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[4]Institute of Immunology & Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[5]College of Computer Science, Sichuan University, Chengdu, 610065, China
Currently, the antitumor efficacy of chimeric antigen receptor T cells in solid tumors is modest. Both chemokines and their receptors play a key role in the proliferation of cancer cells, tumor angiogenesis, organ-selective metastasis and migration of immune cells to solid tumors. Unfortunately, frequent chemokine/chemokine receptor 'mismatch' between effector cells and the tumor microenvironment results in inefficient T-cell infiltration and antitumor efficacy. Thus, reversing the 'mismatch' of chemokines and chemokine receptors appears to be a promising method for promoting T-cell infiltration into the tumor and enhancing their antitumor efficacy. In this review, we discuss functions of the chemokine/chemokine receptor axis in cancer immunity and the current understanding, challenges and prospects for improving the effect of chimeric antigen receptor T cells by reversing the mismatch between chemokines and chemokine receptors.
基金：
This work was supported by the Post-Doctor Research Project, West China Hospital, Sichuan University (grant number
2020HXBH124).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区免疫学
最新[2023]版：
大类|4 区医学
小类|4 区免疫学
第一作者：
第一作者机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China[2]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, & Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China[3]Laboratory of Human Diseases & Immunotherapies, West China Hospital, Sichuan University, Chengdu, 610041, China[4]Institute of Immunology & Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, China
通讯作者：
通讯机构：[1]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China[2]State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, & Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China
推荐引用方式(GB/T 7714)：
Zhang Peng-Fei,Wang Chuang,Zhang Le,et al.Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.[J].Immunotherapy.2022,14(6):459-473.doi:10.2217/imt-2021-0228.
APA：
Zhang Peng-Fei,Wang Chuang,Zhang Le&Li Qiu.(2022).Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells..Immunotherapy,14,(6)
MLA：
Zhang Peng-Fei,et al."Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.".Immunotherapy 14..6(2022):459-473
